CompletedNCT05399498
Single-dose psilocybin study for depression and borderline personality
About this title
Read the official source — NCT05399498Medication studyAges 18–65United StatesPersonality disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- ChicagoSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 1, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 10
- Sponsor
- University of Chicago
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05399498
- Official title
Show the full official title
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chicago
Registry details
Registry conditions (original wording)
Borderline Personality Disorder; Major Depressive Disorder
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Chicago, a university.
Did this study involve medication?
Yes. The study involved medication, including Psilocybin.
Who was this study for?
Listed age limits: 18 years to 65 years.
